An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 9/28/2018 |
| Start Date: | August 3, 2018 |
| End Date: | July 25, 2019 |
| Contact: | Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, |
| Email: | Clinical.Trials@bms.com |
| Phone: | please email: |
A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunologic Effects of BMS-986256, and a Relative Bioavailability Study in Healthy Participants
The purpose of this study is to evaluate the effects of the experimental medication
BMS-986256 in healthy participants.
BMS-986256 in healthy participants.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- Weight ≥ 50 kg and body mass index (BMI) between 18.0 and 32.0 kg/m2 inclusive at
screening
- Participants must not be current users (within 6 months before screening) of tobacco
or tobacco- or nicotine-containing products; they must also be willing to refrain from
using any of these products during their participation in the study
- A negative QuantiFERON®-TB Gold test result at screening or documentation of a
negative result within 3 months before screening
Exclusion Criteria:
- Previous participation in the current study or previous exposure within 6 weeks before
study drug administration for non-biologics and 12 weeks before study drug
administration for biologics
- Inability to tolerate oral medication
- Inability to tolerate venipuncture, or inadequate venous access
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
2
sites
Click here to add this to my saved trials
